Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia
| Autor: | Gerrassimos Pangalis, N. Anagnostopoulos, Constantinos Bourantas, Athanasios Anagnostopoulos, Constantinos Zervas, Marie C Kyrtsonis, Meletios A. Dimopoulos, Athanasios Zomas |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Antineoplastic Agents Gastroenterology Antibodies Monoclonal Murine-Derived Hemoglobins Serum albumin level Predictive Value of Tests Internal medicine medicine Humans In patient Serum Albumin Aged CD20 Aged 80 and over biology business.industry Macroglobulinemia Antibodies Monoclonal Middle Aged Treatment Outcome Active agent Drug Resistance Neoplasm Immunology biology.protein Disease Progression Rituximab Female Immunoglobulin Light Chains Monoclonal protein Waldenstrom Macroglobulinemia business medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1526-9655 |
| Popis: | Rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia. However, many patients do not respond to this agent and several others develop secondary resistance. In order to identify clinical and laboratory parameters that could predict a higher likelihood for response, we evaluated 54 patients who were treated with single-agent rituximab. Twenty-four patients (44%)exhibitedor = 50% reduction of serum monoclonal protein. Previously untreated and pretreated patients had the same probability for response. Low response rates were noted in patients with serum monoclonal protein levelor = 40 g/L (17%) and serum albumin level35 g/L (14%). Furthermore, a multivariate analysis indicated that high serum monoclonal protein and low albumin were the dominant variables associated with shorter time to progression. The presence of 2, 1, or none of these variables was associated with median times to progression of 4 months, 11 months, and approximately 48 months, respectively. We conclude that patients with low levels of monoclonal protein and normal albumin are the best candidates for treatment with rituximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect